Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of CHIKV VLP vaccine in healthy adults and adolescents
2024-000481-17Phase 3
- Sponsor
- Bavarian Nordic
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of CHIKV VLP vaccine in Chikungunya (CHIKV) (4 cohorts), sponsored by Bavarian Nordic. Primary endpoint: Proportion maintaining anti-CHIKV neutralizing antibody titer at least 100.
02
Drugs
CHIKV VLP vaccine
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on 2024-000481-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000481-17.